|
1
|
Saus J, Wieslander J, Langeveld JP,
Quinones S and Hudson BG: Identification of the Goodpasture antigen
as the alpha3(IV) chain of collagen IV. J Biol Chem.
263:13374–13380. 1988.
|
|
2
|
Hudson BG, Reeders ST and Tryggvason K:
Type IV collagen: structure, gene organization, and role in human
diseases. Molecular basis of Goodpasture and Alport syndromes and
diffuse leiomyomatosis. J Biol Chem. 268:26033–26036.
1993.PubMed/NCBI
|
|
3
|
Hamano Y and Kalluri R: Tumstatin, the NC1
domain of alpha3 chain of type IV collagen, is an endogenous
inhibitor of pathological angiogenesis and suppresses tumor growth.
Biochem Biophys Res Commun. 333:292–298. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hamano Y, Zeisberg M, Sugimoto H, Lively
JC, Maeshima Y, Yang C, Hynes RO, Werb Z, Sudhakar A and Kalluri R:
Physiological levels of tumstatin, a fragment of collagen IV alpha3
chain, are generated by MMP-9 proteolysis and suppress angiogenesis
via alphaV beta3 integrin. Cancer Cell. 3:589–601. 2003. View Article : Google Scholar
|
|
5
|
Maeshima Y, Yerramalla UL, Dhanabal M,
Holthaus KA, Barbashov S, Kharbanda S, Reimer C, Manfredi M,
Dickerson WM and Kalluri R: Extracellular matrix-derived peptide
binds to αvβ3 integrin and inhibits angiogenesis. J Biol Chem.
276:31959–31968. 2001.
|
|
6
|
Sudhakar A, Sugimoto H, Yang C, Lively JC,
Zeisberg M and Kalluri R: Human tumstatin and human endostatin
exhibit distinct antiangiogenic activities mediated by αvβ3 and
α5β1 integrins. Proc Natl Acad Sci USA. 100:4766–4771.
2003.PubMed/NCBI
|
|
7
|
Esipov R, Beyrakhova K, Likhvantseva V, et
al: Antiangiogenic and antivascular effects of a recombinant
tumstatin-derived peptide in a corneal neovascularization model.
Biochimie. 94:1368–1375. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Maeshima Y, Colorado PC, Torre A, Holthaus
KA, Grunkemeyer JA, Ericksen MB, Hopfer H, Xiao Y, Stillman IE and
Kalluri R: Distinct antitumor properties of a type IV collagen
domain derived from basement membrane. J Biol Chem.
275:21340–21348. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pasco S, Ramont L, Venteo L, Pluot M,
Maquart FX and Monboisse JC: In vivo overexpression of tumstatin
domains by tumor cells inhibits their invasive properties in a
mouse melanoma model. Exp Cell Res. 301:251–265. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Maeshima Y, Sudhakar A, Lively JC, Ueki K,
Kharbanda S, Kahn CR, Sonenberg N, Hynes RO and Kalluri R:
Tumstatin, an endothelial cell-specific inhibitor of protein
synthesis. Science. 295:140–143. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Maeshima Y, Colorado PC and Kalluri R: Two
RGD-independent alpha vbeta 3 integrin binding sites on tumstatin
regulate distinct anti-tumor properties. J Biol Chem.
275:23745–23750. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Joshi M: The importance of L-arginine
metabolism in melanoma: an hypothesis for the role of nitric oxide
and polyamines in tumor angiogenesis. Free Radic Biol Med.
22:573–578. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kucharzewska P, Welch JE, Svensson KI and
Belting M: The polyamines regulate endothelial cell survival during
hypoxic stress through PI3K/AKT and MCL-1. Biochem Biophys Res
Commun. 380:413–418. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Auvinen M: Cell transformation, invasion,
and angiogenesis: a regulatory role for ornithine decarboxylase and
polyamines? J Natl Cancer Inst. 89:533–537. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pegg AE: Polyamine metabolism and its
importance in neoplastic growth and a target for chemotherapy.
Cancer Res. 48:759–774. 1988.
|
|
16
|
Takigawa M, Ishida H, Takano T and Suzuki
F: Polyamine and differentiation: induction of ornithine
decarboxylase by parathyroid hormone is a good marker of
differentiated chondrocytes. Proc Natl Acad Sci USA. 77:1481–1485.
1980. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kubota S, Kiyosawa H, Nomura Y, Yamada T
and Seyama Y: Ornithine decarboxylase overexpression in mouse
10T1/2 fibroblasts: cellular transformation and invasion. J Natl
Cancer Inst. 89:567–571. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Auvinen M, Laine A, Paasinen-Sohns A,
Kangas A, et al: Human ornithine decarboxylase-overproducing NIH3T3
cells induce rapidly growing, highly vascularized tumors in nude
mice. Cancer Res. 57:3016–3025. 1997.
|
|
19
|
Auvinen M, Paasinen A, Andersson LC and
Hölttä E: Ornithine decarboxylase activity is critical for cell
transformation. Nature. 360:355–358. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Takigawa M, Enomoto M, Nishida Y, Pan HO,
Kinoshita A and Suzuki F: Tumor angiogenesis and polyamines:
alpha-difluoromethylornithine, an irreversible inhibitor of
ornithine decarboxylase, inhibits B16 melanoma-induced angiogenesis
in ovo and the proliferation of vascular endothelial cells in
vitro. Cancer Res. 50:4131–4138. 1990.
|
|
21
|
Takahashi Y, Mai M and Nishioka K:
Alpha-difluoromethylornithine induces apoptosis as well as
anti-angiogenesis in the inhibition of tumor growth and metastasis
in a human gastric cancer model. Int J Cancer. 85:243–247. 2000.
View Article : Google Scholar
|
|
22
|
Nemoto T, Hori H, Yoshimoto M, Seyama Y
and Kubota S: Overexpression of ornithine decarboxylase enhances
endothelial proliferation by suppressing endostatin expression.
Blood. 99:1478–1481. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang B, Liu XX, Zhang Y, Jiang CY, Hu HY
and Gong L: The screening of the sensitive antisense target in the
ODC mRNA. J Shandong Univ. 8:146–150. 2005.
|
|
24
|
Xu CX, Liu XX, Hou GS, Yan YF, Chen SM,
Wang W, Jiang GS, Liu B and Xin JX: The expression of tumstatin is
down-regulated in renal carcinoma. Mol Biol Rep. 37:2273–2277.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Folkman J: Angiogenesis in cancer,
vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Folkman J and Shing Y: Angiogenesis. J
Biol Chem. 267:10931–10934. 1992.
|
|
27
|
Liekens S, De Clercq E and Neyts J:
Angiogenesis: regulators and clinical applications. Biochem
Pharmacol. 61:253–270. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Harris AL: Angiogenesis as a new target
for cancer control. EJC (Suppl). 2:1–12. 2003. View Article : Google Scholar
|
|
29
|
Folkman J: Tumor angiogenesis: therapeutic
implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hanahan D and Folkman J: Patterns and
emerging mechanisms of the angiogenic switch during tumorigenesis.
Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang YP, Xu CX, Hou GS, Xin JX, Wang W and
Liu XX: Effects of eukaryotic expression plasmid encoding human
tumstatin gene on endothelial cells in vitro. Chin Med J (Engl).
123:2269–2273. 2010.PubMed/NCBI
|
|
32
|
O'Reilly MS, Boehm T, Shing Y, Fukai N,
Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR and Folkman J:
Endostatin: an endogenous inhibitor of angiogenesis and tumor
growth. Cell. 88:277–285. 1997. View Article : Google Scholar
|
|
33
|
Chung IS, Son YI, Ko YJ, Baek CH, Cho JK
and Jeong HS: Peritumor injections of purified tumstatin delay
tumor growth and lymphatic metastasis in an orthotopic oral
squamous cell carcinoma model. Oral Oncol. 44:1118–1126. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bertolini F, Fusetti L, Mancuso P, Gobbi
A, Corsini C, Ferrucci PF, Martinelli G and Pruneri G: Endostatin,
an anti-angiogenic drug, induces tumor stabilization after
chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of
human high-grade non-Hodgkin lymphoma. Blood. 96:282–287.
2000.PubMed/NCBI
|
|
35
|
te Velde EA, Vogten JM, Gebbink MF, van
Gorp JM, et al: Enhanced antitumor efficacy by combining
conventional chemotherapy with angiostatin or endostatin in a liver
metastasis model. Br J Surg. 89:1302–1309. 2002.PubMed/NCBI
|
|
36
|
Yao B, He QM, Tian L, Xiao F, Jiang Y,
Zhang R, et al: Enhanced antitumor effect of the combination of
tumstatin gene therapy and gemcitabine in murine models. Hum Gene
Ther. 16:1075–1086. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Moshier JA, Dosescu J, Skunca M and Luk
GD: Transformation of NIH/3T3 cells by ornithine decarboxylase
overexpression. Cancer Res. 53:2618–2622. 1993.PubMed/NCBI
|
|
38
|
Meyskens FL Jr and Gerner EW: Development
of difluoromethyornithine (DFMO) as a chemoprevention agent. Clin
Cancer Res. 5:945–951. 1999.PubMed/NCBI
|
